- Privately held Enteris BioPharma initiates a feasibility study agreement with Sanofi (NASDAQ:SNY -0.2%) to develop an oral formulation of one of Sanofi's preclinical-stage peptides for the treatment of type 2 diabetes (T2D). The effort will leverage Enteris' platform Peptelligence, which is designed to increase the solubility and absorption of peptides and small molecules while reducing variability and food effects.
- Financial terms are not disclosed.